Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. Among authors: mosenzon o. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, Rasmussen S, Bain SC. Tuttle KR, et al. Among authors: mosenzon o. Kidney Int. 2023 Apr;103(4):772-781. doi: 10.1016/j.kint.2022.12.028. Epub 2023 Feb 2. Kidney Int. 2023. PMID: 36738891 Free article.
The authors reply.
Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Mosenzon O, Rasmussen S, Bain SC. Tuttle KR, et al. Among authors: mosenzon o. Kidney Int. 2023 Sep;104(3):619. doi: 10.1016/j.kint.2023.06.008. Kidney Int. 2023. PMID: 37599024 No abstract available.
The importance of early diagnosis and intervention in chronic kidney disease: Calls-to-action from nephrologists based mainly in Central/Eastern Europe.
Covic A, Säemann M, Filipov J, Gellert R, Gobin N, Jelaković B, Kabulbayev K, Luman M, Miglinas M, Mosenzon O, Okša A, Radovic M, Rozen-Zvi B, Ziediņa I, Tesar V. Covic A, et al. Among authors: mosenzon o. Kidney Blood Press Res. 2024 Mar 5. doi: 10.1159/000538165. Online ahead of print. Kidney Blood Press Res. 2024. PMID: 38442701 Free article. Review.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Billings LK, Green JB, Koya D, Mosenzon O, Pantalone KM, Ahlers C, Lage A, Lawatscheck R, Scalise A, Bakris GL. Rossing P, et al. Among authors: mosenzon o. Diabetes Obes Metab. 2023 Oct;25(10):2989-2998. doi: 10.1111/dom.15197. Epub 2023 Jul 4. Diabetes Obes Metab. 2023. PMID: 37402696 Clinical Trial.
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.
Schechter M, Melzer Cohen C, Zelter T, Yanuv I, Rozenberg A, Chodick G, Karasik A, Mosenzon O. Schechter M, et al. Among authors: mosenzon o. Diabetes Obes Metab. 2023 Oct;25(10):3054-3058. doi: 10.1111/dom.15172. Epub 2023 Jun 29. Diabetes Obes Metab. 2023. PMID: 37385956 No abstract available.
154 results